| Literature DB >> 24765156 |
Johji Imura1, Shinichi Hayashi1, Kazuhito Ichikawa2, Shigeharu Miwa1, Takahiko Nakajima1, Kazuhiro Nomoto1, Koichi Tsuneyama1, Tatsuya Nogami3, Hitoaki Saitoh3, Takahiro Fujimori2.
Abstract
In spite of the evidence that the malignant transformation of gastric hyperplastic polyps (HPs) is a rare event, it must always be taken into account during diagnosis. The aim of the current study was to clarify the mechanism of the malignant transformation of gastric hyperplasia polyps, with focus on phenotypic expression, cell proliferation and p53 overexpression. Immunohistochemistry for mucin phenotypic markers, including MUC1, MUC2, MUC5AC, MUC6, tight junction factors (claudin-3, -4 and -18), an intestinal phenotypic marker [caudal type homeobox 2 (Cdx2)], Ki-67 proliferative index and p53 overexpression, was performed on archival specimens of gastric polyps excised from six patients. Histologically, the intermingled components of several lesions were present in these polyps. Furthermore, the cancer components were predominantly differentiated adenocarcinoma. Immunohistochemically, all hyperplastic components expressed MUC5AC, but did not exhibit positivity for MUC2. Additionally, the majority of hyperplastic components were immunonegative for claudin-3, while claudin-3 positivity was observed in the majority of areas of dysplasia and carcinoma. Expression of claudin-4 was also observed in the majority of cases and claudin-18 was preserved in the hyperplastic, dysplastic and adenocarcinomatous lesions of all cases. Nuclear accumulation of Cdx2 was detected in almost all the samples with dysplasia and carcinoma, while nuclear p53 was detected in 24-80% of the dysplastic areas and >85% of the cancer components. The Ki-67 labeling index appeared to correlate with neoplastic progression. The observations provided evidence that the mechanism underlying malignant transformation of gastric HPs may occur by multistep carcinogenesis, such as the hyperplasia-adenoma (dysplasia)-adenocarcinoma sequence, and these neoplastic cells may acquire various phenotypes during this process.Entities:
Keywords: clinicopathological study; gastric hyperplastic polyp; malignant transformation; mucin phenotype; p53; proliferative activity; tight junction
Year: 2014 PMID: 24765156 PMCID: PMC3997677 DOI: 10.3892/ol.2014.1932
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Figure 1Endoscopic observations. Multiple polyps were shown to be scattered throughout the residual stomach in case 1.
List of patient characteristics.
| Patient | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| Variable | 1 | 2 | 3 | 4 | 5 | 6 |
| Age, years | 69 | 78 | 65 | 68 | 75 | 66 |
| Gender | M | F | M | M | F | M |
| Location | RS | B | A | B | A | B |
| Lesion | M | S | S | S | S | M |
| Size, cm | 4.0 | 2.5 | 3.0 | 1.0 | 2.5 | 2.6 |
RS, residual stomach; B, body; A, antrum.
M, multiple; S, solitary. M, male, F, female.
Figure 2Histological observations of resected specimen of case 1 (H&E staining). (a) Low power view (magnification, ×4) of the carcinomatous component in a gastric hyperplastic polyp, consisting of (b) hyperplastic foveolar (magnification, ×10), (c) dysplasia (magnification, ×10) and (d) differentiated adenocarcinoma (magnification, ×10).
Figure 3Immunohistochemical observations for MUC5AC in case 3: (a) foveolar hyperplasia, (b) dysplasia and (c) adenocarcinoma. Magnification, ×10.
Figure 4Immunohistochemical observations for caudal type homeobox 2 in case 4: (a) foveolar hyperplasia, (b) dysplasia and (c) adenocarcinoma. Magnification, ×10.
Figure 5Immunohistochemical observations for claudin-4 in case 1: (a) foveolar hyperplasia, (b) dysplasia and (c) adenocarcinoma. Magnification, ×10.
Results of immunohistochemical analysis.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||||||||
| Markers | H | D | C | H | D | C | H | D | C | H | D | C | H | D | C | H | D | C |
| MUC1 | − | − | − | − | − | − | − | + | + | − | + | + | − | − | − | − | + | + |
| MUC2 | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
| MUC5AC | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | − | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| MUC6 | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
| Cdx2 | − | − | − | − | + | ++ | + | ++ | ++ | − | ++ | ++ | − | ++ | ++ | − | ++ | ++ |
| Claudin-3 | − | + | + | − | + | + | − | − | + | − | − | − | − | − | + | − | − | + |
| Claudin-4 | ++ | ++ | ++ | − | ++ | ++ | − | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| Claudin-18 | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| p53, % | <5 | 24 | 85 | 12 | 80 | 90 | <5 | 80 | 90 | <5 | 60 | 90 | <5 | 75 | 85 | <5 | 65 | 90 |
H, hyperplasia; D, dysplasia; C, carcinoma; Cdx2, caudal type homeobox 2.